The growth of the In-Vitro Diagnostics/IVD Market is mainly driven by the rising geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, increasing adoption of fully automated and POC instruments in developed regions, growing awareness regarding diseases diagnosis in developing regions, and growing R&D investments by industry players to launch new IVD products. Also, the development of disease-specific markers and tests is expected to offer potential growth opportunities to market players in the coming years. However, the unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.
The global In-Vitro Diagnostics Market is projected to
reach USD 113.1 billion by 2026
from USD 98.2 billion in 2021, at a CAGR
of 2.9% during the forecast period.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703
Scope of the Report:
By Product and Service
- Reagents
& Kits
- Instruments
- Services
- Data
Management Software
By Technology
- Immunoassay/
Immunochemistry
- Clinical
chemistry
- Molecular
diagnostics
- Hematology
- Microbiology
- Coagulation
and Hemostasis
- Urinalysis
- Other
Technologies
By Application
- Infectious
diseases
- Diabetes
- Oncology
- Cardiology
- Drug
Testing/ Pharmacogenomics
- Autoimmune
diseases
- HIV/AIDS
- Nephrology
- Other
applications
By End User
- Hospital
laboratories
- Clinical
laboratories
- Point-of-care
testing centers
- Academic
institutes
- Patients
- Other
end users
By Country
- North
America
- US
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest
of Europe
- Asia
Pacific
- China
- Australia
- Japan
- India
- Rest
of APAC
- Latin
America
- Brazil
- Rest
of LATAM
- Middle
East and Africa
- Turkey
- Rest
of MEA
Market Segmentation: -
In this report, the IVD market is segmented based on
product & service, technology, application, end user, and region.
Based on product and service, the In-Vitro
Diagnostics Market is segmented into reagents & kits, instruments,
services, and data management software. The reagents & kits segment
accounted for the largest share of 68.1% of the market in 2020. Accessibility
to a wide range of reagents and the need for reliable, specific, and faster
detection of chronic diseases and genetic disorders in the early stages are
expected to drive the growth of this segment.
Based on application, the In-Vitro Diagnostics
Market is segmented into infectious diseases, diabetes, Oncology, cardiology,
drug testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and
other applications. In 2020, infectious diseases accounted for 34.1% of the IVD
market. The large share of this segment can be attributed to the rising
prevalence of infectious diseases and multi-drug-resistant infectious diseases
and the growing need for effective diagnostic tools for these diseases.
However, the oncology segment is projected to grow at the highest CAGR of 6.6%
during the forecast period. The increasing number of cancer cases across the
globe, the growing demand for personalized medicine, and the availability of
funding for cancer research are the major factors driving the market growth.
Based on technology, the In-Vitro Diagnostics Market
is segmented into immunoassay/immunochemistry, clinical chemistry, molecular
diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis
and other technologies. The immunoassay/immunochemistry segment accounted for
31% of the IVD technologies market in 2020. The growing preference for these
technologies in clinical diagnostics over conventional methods and the ability
of immunoassay/immunochemistry technologies to offer faster results with high
sensitivity and accuracy are contributing to the growth of this market segment.
Based on the end user, the In-Vitro Diagnostics
Market is segmented into hospital laboratories, clinical laboratories, academic
institutes, POC (point-of-care) testing centers, patients, and other end users.
In 2020, hospital laboratories accounted for the largest share of 47% of the
market, followed by clinical laboratories (23.8%) and POC testing centers
(13%). Many diagnostic tests are carried out in hospitals. The acquisition of
smaller physician practices and groups by hospitals is becoming a noticeable
trend in the US healthcare industry; the continuation of this trend will
support the market for hospital laboratories.
Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=703
Regional Analysis :-
The In-Vitro Diagnostics Market is divided into five
major regions— North
America, Europe, Asia Pacific, Latin America,
and the Middle East & Africa.
In 2020, North America accounted
for the largest share of 39.8% of the market, followed by Europe (28%), Asia Pacific (22.9%), Latin America (6.5%),
and the Middle East & Africa (2.9%).
The In-Vitro Diagnostics/IVD Market in North
America is well established, with the US being the
major market in this region.
Key Market Players:
Roche Diagnostics (Switzerland),
Siemens Healthineers (Germany),
Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are
the leading players in this market. Other players in this market are Johnson
& Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories
(US), Sysmex Corporation (Japan),
bioMérieux (France),
DiaSorin (Italy),
Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).
No comments:
Post a Comment